Global Gastrointestinal Stromal Tumors Therapeutics Market Strategic Research Report
By Type: Oral, Parenteral
By Application: Hospital pharmacies, Retail pharmacies, Online pharmacies
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: AB Science SA, AROG Pharmaceuticals Inc., Ascentage Pharma Group International, Bayer AG, Blueprint Medicines Corp., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Deciphera Pharmaceuticals Inc., Ipsen Pharma, Mendus AB, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Xencor Inc.
Overview
Scope of the Report
The global Gastrointestinal Stromal Tumors Therapeutics market size is estimated at US$ 1.26 billion in 2025 and is projected to reach US$ 1.92 billion by 2031, growing at a CAGR of 7.37% from 2025 to 2031.
The report segments the Gastrointestinal Stromal Tumors Therapeutics market by Route Of Administration, Distribution Channel and Therapy, and profiles 16 leading companies including AB Science SA, AROG Pharmaceuticals Inc., Ascentage Pharma Group International and Bayer AG.
This report presents a comprehensive overview of the global Gastrointestinal Stromal Tumors Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Route Of Administration
- Oral
- Parenteral
Segment by Therapy
- Targeted therapy
- Chemotherapy
- Immunotherapy
- Others
Segment by Application
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global Gastrointestinal Stromal Tumors Therapeutics market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Hospital pharmacies, Retail pharmacies, Online pharmacies evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global Gastrointestinal Stromal Tumors Therapeutics Market Strategic Research Report snapshot, 2025–2031
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 Oral
- 3.1.3 Parenteral
- 3.1.4 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Hospital pharmacies
- 4.1.3 Retail pharmacies
- 4.1.4 Online pharmacies
- 4.1.5 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 India
- 6.1.4 South Korea
- 6.1.5 Australia
- 6.1.6 Indonesia
- 6.1.7 Thailand
- 6.1.8 Malaysia
- 6.1.9 Vietnam
- 6.1.10 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 United Kingdom
- 6.3.3 France
- 6.3.4 Italy
- 6.3.5 Spain
- 6.3.6 Russia
- 6.3.7 Netherlands
- 6.3.8 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Saudi Arabia
- 6.4.2 United Arab Emirates
- 6.4.3 Turkey
- 6.4.4 South Africa
- 6.4.5 Egypt
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Argentina
- 6.5.3 Colombia
- 6.5.4 Chile
- 6.5.5 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 AB Science SA
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2031)
- 8.2 AROG Pharmaceuticals Inc.
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2031)
- 8.3 Ascentage Pharma Group International
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2031)
- 8.4 Bayer AG
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2031)
- 8.5 Blueprint Medicines Corp.
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2031)
- 8.6 Bristol Myers Squibb Co.
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2031)
- 8.7 Daiichi Sankyo Co. Ltd.
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2031)
- 8.8 Deciphera Pharmaceuticals Inc.
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2031)
- 8.9 Ipsen Pharma
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2031)
- 8.10 Mendus AB
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2031)
- 8.11 Merck KGaA
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2031)
- 8.12 Novartis AG
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2031)
- 8.13 Pfizer Inc.
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2031)
- 8.14 Sun Pharmaceutical Industries Ltd.
- 8.14.1 Company Overview
- 8.14.2 Key Products & Segments
- 8.14.3 Financial Performance (2023–2025)
- 8.14.4 Business Strategy
- 8.14.5 SWOT Analysis
- 8.14.6 Strategic Implications (2026–2031)
- 8.15 Takeda Pharmaceutical Co. Ltd.
- 8.15.1 Company Overview
- 8.15.2 Key Products & Segments
- 8.15.3 Financial Performance (2023–2025)
- 8.15.4 Business Strategy
- 8.15.5 SWOT Analysis
- 8.15.6 Strategic Implications (2026–2031)
- 8.16 Xencor Inc.
- 8.16.1 Company Overview
- 8.16.2 Key Products & Segments
- 8.16.3 Financial Performance (2023–2025)
- 8.16.4 Business Strategy
- 8.16.5 SWOT Analysis
- 8.16.6 Strategic Implications (2026–2031)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2031
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
How big is the global Gastrointestinal Stromal Tumors Therapeutics market?
How fast is the Gastrointestinal Stromal Tumors Therapeutics market expected to grow?
How is the Gastrointestinal Stromal Tumors Therapeutics market segmented by route of administration?
What are the key applications of Gastrointestinal Stromal Tumors Therapeutics?
Which companies are profiled in the Gastrointestinal Stromal Tumors Therapeutics market report?
What geographies does the Gastrointestinal Stromal Tumors Therapeutics market analysis include?
Who should buy the Gastrointestinal Stromal Tumors Therapeutics market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Related reports
Navadhi Market Research · Consumer Goods & RetailGlobal Cabinet and Furniture Hardware Market Strategic Research Report
The global cabinet and furniture hardware market is positioned for robust growth through 2031.The global cabinet and furniture hardware market is on a sustained grow…
Navadhi Market Research · Consumer Goods & RetailGlobal Model Context Protocol Retail Integration Market Strategic Research Report
The Global Model Context Protocol (MCP) Retail Integration Market sits at the intersection of large language model infrastructure and enterprise retail technology, r…
Navadhi Market Research · Consumer Goods & RetailGlobal Retail Generative Engine Optimization Software Market Strategic Research Report
The global retail generative engine optimization (GEO) software market sits at the intersection of artificial intelligence-driven search transformation and the struc…
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a sample report
Receive a sample of Global Gastrointestinal Stromal Tumors Therapeutics Market Strategic Research Report before you buy. Please note that the sample report contains full table of contents, extracts of selected chapters and the list of exhibits. Charts and detailed figures are reserved for the full report; the sample shows only the headline numbers already published on this page.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Leading Brands in This Industry
